Market Place
Sourcing Support
DDW 2025 Data Shows TissueCypher® Test Identifies Esophageal Canc
02 May 2025 //
GLOBENEWSWIRE
Castle Dx Test Outperforms in Melanoma Node Risk
30 Apr 2025 //
GLOBENEWSWIRE
DecisionDx-Melanoma Test Tops 200K Orders for Patients
28 Apr 2025 //
GLOBENEWSWIRE
Data at AACR Shows DecisionDx Melanoma Predicts Metastasis
25 Apr 2025 //
GLOBENEWSWIRE
Castle Biosciences to Release Q1 2025 Results, Host Call May 5
14 Apr 2025 //
GLOBENEWSWIRE
Castle Biosciences Strengthens Esophageal Cancer Awareness Commit
08 Apr 2025 //
GLOBENEWSWIRE
Castle Biosciences Wins Top Workplaces USA Award 4th Year
07 Apr 2025 //
GLOBENEWSWIRE
Study Shows Positive Outcomes in Low-Risk Melanoma Patients
03 Apr 2025 //
GLOBENEWSWIRE
Castle Bio`s DecisionDx-Melanoma Test Supports Risk-Based Care
01 Apr 2025 //
GLOBENEWSWIRE
Castle Bio` DecisionDx®-SCC Data Top Five Abstract at NCCN 2025
28 Mar 2025 //
GLOBENEWSWIRE
Castle Biosciences Dermatology Data To Be Presented At AAD 2025
07 Mar 2025 //
BUSINESSWIRE
Castle Biosciences Reports Q4 and Full-Year 2024 Results
27 Feb 2025 //
BUSINESSWIRE
Castle Bio to Participate in Upcoming Investor Conferences
25 Feb 2025 //
BUSINESSWIRE
Castle To Present Dermatologic Gene Test Data At Winter Clinical
12 Feb 2025 //
BUSINESSWIRE
Castle Bio Highlights Progress on Atopic Dermatitis Gene Test
23 Dec 2024 //
BUSINESSWIRE
Castle Bio Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
19 Dec 2024 //
BUSINESSWIRE
Castle`s DecisionDx®-Melanoma Aids Melanoma Management
12 Dec 2024 //
BUSINESSWIRE
Castle Bio to Present at Piper Sandler Healthcare Conference
20 Nov 2024 //
BUSINESSWIRE
Castle Bio Presents Melanoma Data at Dermatopathology 66th Meeting
08 Nov 2024 //
BUSINESSWIRE
Castle Biosciences’ Test Reduces Unnecessary SLNB Procedures
06 Nov 2024 //
BUSINESSWIRE
Castle Biosciences to Participate in Upcoming Investor Conferences
28 Oct 2024 //
BUSINESSWIRE
Castle Bio Presents CONNECTION Study Data for DecisionDx®-Melanoma
20 Oct 2024 //
BUSINESSWIRE
Publications Affirm Gene Profile Testing In Melanocytic Lesions
16 Oct 2024 //
BUSINESSWIRE
Castle Biosciences` DecisionDx-SCC Test Data Presented At ASTRO
27 Sep 2024 //
BUSINESSWIRE
Castle Biosciences Reports Second Quarter 2024 Results
05 Aug 2024 //
BUSINESSWIRE
Castle Biosciences turns to former ‘Real Housewife’ for melanoma campaign
23 Jul 2024 //
FIERCE PHARMA
Castle Bio And Teddi Mellencamp Launch Melanoma Awareness Campaign
22 Jul 2024 //
BUSINESSWIRE
DecisionDx-SCC Identifies High-Risk SCC Patients For Adjuvant Radiation
29 May 2024 //
BUSINESSWIRE
Castle Expands Barrett`s Test Evidence At DDW 2024
14 May 2024 //
BUSINESSWIRE
Castle IDgenetix Named Best Mental Health Solution 2024
10 May 2024 //
BUSINESSWIRE
Castle Biosciences Reports First Quarter 2024 Results
02 May 2024 //
BUSINESSWIRE
Presentations of Castle Bio DecisionDx®-Melanoma and DecisionDx®-SCC Tests
04 Apr 2024 //
BUSINESSWIRE
Castle Biosciences Announces Updates to its Board of Directors
27 Mar 2024 //
BUSINESSWIRE
Castle Biosciences to Present at the KeyBanc Capital Markets Forum
12 Mar 2024 //
BUSINESSWIRE
Castle to Present Data Highlighting the Value of its Dermatologic Tests
08 Mar 2024 //
BUSINESSWIRE
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
28 Feb 2024 //
BUSINESSWIRE
Castle`s COO Kristen Oelschlager Selected Among the Top 25 Women Leaders in Bio
09 Jan 2024 //
BUSINESSWIRE
Castle Biosciences Announces Multiple Data Presentations at Annual Meeting
14 Nov 2023 //
BUSINESSWIRE
Castle Biosciences to Release Third Quarter 2023 Financial Results
19 Oct 2023 //
BUSINESSWIRE
Castle Biosciences Presents New Data at ASTRO 2023
03 Oct 2023 //
BUSINESSWIRE
Castle to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
06 Sep 2023 //
BUSINESSWIRE
Castle Biosciences Reports Second Quarter 2023 Results
02 Aug 2023 //
BUSINESSWIRE
Castle Biosciences to Release Second Quarter 2023 Financial Results
19 Jul 2023 //
PRESS RELEASE
Castle Biosciences to Host Second Annual Castle Cares Charity Walk
18 Jul 2023 //
BUSINESSWIRE
Castle Honored as an Arizona Top Workplace for the Second Consecutive Year
17 Jul 2023 //
PRESS RELEASE
Castle to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at AHNS
07 Jul 2023 //
PRESS RELEASE
IDgenetix® Shown to Significantly Improve Medication Response
31 May 2023 //
BUSINESSWIRE
Castle Biosciences gets on board the `Sun Bus` for another year
30 May 2023 //
FIERCE PHARMA
Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions
03 May 2023 //
BUSINESSWIRE
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management
20 Apr 2023 //
BUSINESSWIRE
Castle to Present at the 22nd Annual Needham Virtual Healthcare Conference
12 Apr 2023 //
BUSINESSWIRE
Castle Biosciences Presents Data Demonstrating the Utility of DecisionDx-SCC
15 Nov 2022 //
BUSINESSWIRE
New Data from DECIDE Study Show the Significant Role of DecisionDx
20 Oct 2022 //
BUSINESSWIRE
Castle Biosciences to Release Third Quarter 2022 Financial Results
19 Oct 2022 //
BUSINESSWIRE
Results from a Trial Show That TissueCypher Barrett’s Esophagus Test Results
13 Oct 2022 //
BUSINESSWIRE
Castle Announces Publication Demonstrating the Integration of DecisionDx
23 Sep 2022 //
BUSINESSWIRE
Castle Biosciences Reports Second Quarter 2022 Results
08 Aug 2022 //
BUSINESS WIRE
